抗血管内皮生长因子药物治疗糖尿病黄斑水肿临床试验的研究与进展  

Research and progress in clinical trials of anti-vascular endothelial growth factor drugs in the treatment of diabetic macular edema

作　　者：龚轶 邵彦 李筱荣 Gong Yi;Shao Yan;Li Xiaorong(Tianjin Key Laboratory of Retinal Functions and Diseases,Tianjin Branch of National Clinical Research Centre for Ocular Disease,Eye Institute and School of Optometry,Tianjin Medical University Eye Hospital,Tianjin 300384,China)

机构地区：[1]天津医科大学眼科医院眼视光学院眼科研究所国家眼耳鼻喉疾病临床医学研究中心天津市分中心天津市视网膜功能与疾病重点实验室,天津300384

出　　处：《中华眼底病杂志》2022年第1期66-71,共6页Chinese Journal of Ocular Fundus Diseases

基　　金：国家自然科学基金(81900891);天津市临床重点学科建设项目(TJLCZDXKT004、TJLCZDXKM010、TJLCZDXKQ015)。

摘　　要：糖尿病黄斑水肿(DME)是糖尿病视网膜病变致盲的主要原因之一。近年来,随着血管内皮生长因子(VEGF)在DME中致病作用的认识,国内外已开展了多项玻璃体腔注射抗VEGF药物治疗的临床试验,证明其在提高患者视力和减轻黄斑水肿方面具有显著疗效,已成为DME的一线治疗方法。尽管如此,抗VEGF药物治疗在常规的临床应用中仍然存在诸多挑战,如注射次数频繁、部分患者治疗不敏感等,并且反复注射是否会对视网膜产生损伤仍不明确。DME的病理生理学过程十分复杂,除VEGF外还有许多炎症因子及生长因子参与。长效抗VEGF制剂、针对其他靶点的药物和基因治疗等临床试验也在不断开展。相信随着各项研究的深入和临床试验的进展,抗VEGF药物、其他药物和治疗方法在临床的逐步应用指日可待,未来有望为DME患者提供更方便、更有效的治疗。Diabetic macular edema(DME)is one of the main reasons causing blindness in patients with diabetic retinopathy.In recent years,with the recognition of the pathogenic role of vascular endothelial growth factor(VEGF)in DME,many clinical trials of intravitreal injection of anti-VEGF drugs have been carried out at home and abroad,proving that it has significant effects in improving visual acuity and reducing macular edema,and has become the first-line treatment of DME.However,there are still many challenges in routine clinical application of anti-VEGF drugs,such as frequent injections,insensitivity to treatment,and it is unclear whether repeated injections will cause damage to retina.The pathophysiological process of DME is very complicated,in addition to VEGF,there are many inflammatory factors and growth factors involved.Clinical trials of long-acting anti-VEGF agents,drugs of other targets and gene therapy are also being carried out.It is believed that with the in-depth research and progress of clinical trials,the gradual application of anti-VEGF drugs,other drugs and therapy in clinical practice are just around the corner,which is expected to provide more convenient and effective treatments for DME patients in the future.

关 键 词：糖尿病视网膜病变 黄斑水肿 血管生成抑制剂 临床试验 综述 

分 类 号：R587.2[医药卫生—内分泌] R774.5[医药卫生—内科学]